What is the procedure, for establishing reimbursement for an IVD test product? What companies have been successful and how? What changes will IVD makers face in the near-term. This Kalorama Information report, Reimbursement for In Vitro Diagnostic Tests, answers these questions and provides authoritative data for IVD business planners.
One of the critical factors for the success of an IVD product is reimbursement. Reimbursement is a critical component of the health care landscape and will continue to have a major impact on the continued usage of established products as well as product innovation and the market success of new technologies since products without solid reimbursement will not achieve widespread utilization and/or will not provide the revenues for their developers to continue to introduce new products.
This report, Reimbursement for In Vitro Diagnostic (IVD) Tests examines the U.S. reimbursement system for IVD tests, focusing on key issues of current concern to industry. It covers only commercialized tests, specifically excluding those that are developmental or used primarily for research purposes.
As part of its analysis, the report has the following:
Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends. Case studies of successful reimbursement strategies are included to illustrate how product developers obtain reimbursement for new IVD tests.
Related Reports:The World Market for Flow Cytometry in IVD Applications
Jun 16, 2014 - KLI5271977 - $1,995.00
The United States Market for In Vitro Diagnostic Tests
Mar 18, 2014 - KLI5217921 - $3,995.00
Retail Clinics Market Overview and 2014 Survey Results
Mar 11, 2014 - KLI5215143 - $750.00
The World Market for Hematology
Nov 22, 2013 - KLI5156915 - $3,995.00
The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry
Aug 16, 2013 - KLI5098639 - $995.00
Out of Pocket Healthcare Spending 2013
Jun 18, 2013 - KLI5066012 - $1,500.00
The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives
May 8, 2013 - KLI5036103 - $3,500.00
Retail Clinics: Consumer Attitudes Results of the 2013 Kalorama Survey
Mar 22, 2013 - KLI5007914 - $995.00
IVD Procedure Volume and Pricing Analysis
Jan 31, 2013 - KLI4958744 - $1,995.00
World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas)
Jan 9, 2013 - KLI4939202 - $4,500.00
Questions?Contact a research specialist >
Most Popular ResearchResults of The 2012 Kalorama IVD Procedure Count: White Paper The World Market for Point of Care (POC) Diagnostics World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) Why Epigenomics May Be a Game-Changer in Diagnostics and Pharmaceuticals IVD Procedure Volume and Pricing Analysis White Paper: The Molecular Era in IVD Testing